Share Name Share Symbol Market Type Share ISIN Share Description
Sinclair Pharma LSE:SPH London Ordinary Share GB0033856740 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.25p +1.15% 22.00p 1,165,575 10:55:12
Bid Price Offer Price High Price Low Price Open Price
22.00p 22.20p 22.00p 22.00p 22.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 45.5 -38.2 -5.9 - 110.83

Sinclair Pharma (SPH) Latest News

More Sinclair Pharma News
Sinclair Pharma Takeover Rumours

Sinclair Pharma (SPH) Share Charts

1 Year Sinclair Pharma Chart

1 Year Sinclair Pharma Chart

1 Month Sinclair Pharma Chart

1 Month Sinclair Pharma Chart

Intraday Sinclair Pharma Chart

Intraday Sinclair Pharma Chart

Sinclair Pharma (SPH) Discussions and Chat

Sinclair Pharma Forums and Chat

Date Time Title Posts
06/3/201815:37Sinclair Pharma Thread1,723
15/10/201414:32TipTV: Sinclair Pharmaceuticals to head back towards 30p!-
21/2/200508:49Small cap Sinclair Pharma - Walmart inc.-

Add a New Thread

Sinclair Pharma (SPH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Sinclair Pharma trades in real-time

Sinclair Pharma (SPH) Top Chat Posts

Sinclair Pharma Daily Update: Sinclair Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SPH. The last closing price for Sinclair Pharma was 21.75p.
Sinclair Pharma has a 4 week average price of 20.90p and a 12 week average price of 20.50p.
The 1 year high share price is 35.25p while the 1 year low share price is currently 20.50p.
There are currently 503,768,952 shares in issue and the average daily traded volume is 136,465 shares. The market capitalisation of Sinclair Pharma is £110,829,169.44.
red ninja: Mmm given the low share price no one has come in with a bid even though Sinclair shareholders of recent years are familiar with takeover talk which somehow never seems to amount to much.
dealit: Encouraging share price rise today, maybe announcement on new distribution partnership is reason why share price has moved North today. IMHO the share price will slowly go upwards in anticipation of result statement next month.
dealit: 3 positive announcements good to see, lets hope that the share price keeps moving North.
haroldthegreat: Write up in evening standard on Friday on apprentice winner Dr Leah says she is using silhouette in her clinics for non surgical face lifts.that should increase demand by patients for the product in London. She and Lord Sugar would have done very careful research before using the product in their 3 clinics as they are in the public eye and cannot be associated with a product that doesn't live up to expectations. Whereas any other salon or plastic surgeon stating they use the product would have limited effect on sales the apprentice effect should see a significant uplift on future sales. This is the first time I have seen it mentioned in any publication I read. Hopefully it should result in a share price increase next week in anticipation of increased sales .
steeplejack: A long,meandering statement."Local issues"?....what happened,someone go on strike.We can't apply the expression "firing on all cylinders".Both geographically and divisionally,there are weak spots.The share price is likely to hang around current levels given that recent price weakness has probably discounted this rather bland message.
maxwellsdemon: It is ABZA. Top mover today.
digger18: I tend to agree and feel that this is down to the significant changes made with the restructuring and the market wants to see a good set of figures. If this comes to fruition which I believe will be the case, then we should see the share price reflecting performance. It will be interesting to see the cash burn relating to the new marketing strategy.
steeplejack: Since the stock is not overtly expensive,a share price falling towards a three year low is bound to raise concern.No smoke without fire etc.I'm reassured that Tosca are more than capable of addressing any problems,if indeed there are any.
dealit: The only thing that I cannot understand is the share price, the potential growth here is massive, growth usually drives a Companies share price North.
soundbuy: H/T FT AV Stifel BUY Sinclair Pharma has announced it has signed a licensing agreement with Almirall’s aesthetics business Thermigen to launch, distribute and promote Silhouette InstaLift in the US for an initial four-year period. Sinclair has also provided a 3Q FY16 trading update with revenues of £8.9m in the period. The decision to license Silhouette to Almirall marks the end of the company’s strategic review and hence the offer period. The deal also means Sinclair will no longer have to fully fund the product’s US launch. With £45m net cash at 31 March 2016, the business is well funded to profitability. We value Sinclair on a sum-of-the-parts basis at 49p/share, offering significant upside to the current share price. Much of this value rests with Silhouette Instalift in the US. Partnering with an established aesthetics company like Thermigen gives us increased confidence that the products potential can be successfully realised. Buy. Sinclair signs distribution and marketing agreement with Thermigen. As part of the deal, Thermigen will promote Sinclair’s aesthetic product Silhouette InstaLift with its 55 rep sales force with a further 10 reps added to specifically promote Silhouette. The distribution agreement, which is initially for a four-year term, provides for Sinclair to repatriate rights from the end of 2018. Thermigen is a fast growing aesthetics business that was acquired by Almirall in February 2016. It has an installed base of over 1,000 systems in the US that provide a range of thermal aesthetic treatments. Silhouette US launch ongoing. Sinclair initiated US prelaunch activities for Silhouette InstaLift in 4Q15 and has now trained 75 physicians in using the product. Thermigen will formally launch the product later this month. Trading update. Along with this announcement, Sinclair has provided a trading update for 1Q16. Sales in the period were £8.9m, significantly ahead of the £7.7m achieved in 2H15 and given likely seasonal demand for aesthetics in 2Q16, on track for our FY16 forecasts. Sinclair has announced it will change its year-end to 31 December to align the business with industry peers. Brazilian affiliate established for Silhouette Soft effective 1 July 2016. The deal is expected to be immediately accretive. Reiterate Buy. We believe the licensing of distribution and marketing rights to Thermigen not only reduces the investment needed to establish Silhouette InstaLift in the US but also increases the chances of a successful launch given Thermigen’s proven experience. Given Sinclair retains the long-term value in Silhouette InstaLift in the US, we retain our 49p sum-of-the-parts valuation.
Sinclair Pharma share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20180320 13:43:32